On Saturday, the World Health Organization announced that it had stopped testing combination drugs for the treatment of HIV lopinavir and ritonavir as a combination treatment for hospitalized patients with coronavirus, after intermediate results showed that the drugs “give a slight decrease or do not reduce mortality” in patients with Covid-19.
Several thousand patients were included in the lopinavir / ritonavir treatment group for solidarity trials led by WHO, as well as in a separate study of these drugs led by the UK.
A Solidarity Test was established by WHO to find effective Covid-19 treatment for patients. Started with five hands looking at treatment options: standard service; remdesivir; hydroxychloroquine; lopinavir / ritonavir; and lopanivir / ritonavir in combination with interferon.
On Saturday, WHO also announced that it was stopping the use of hydroxychloroquine in its global study. The U.S. agency earlier announced it was abandoning the cure for malaria, which U.S. President Donald Trump is protecting against the virus, despite numerous studies showing that it is not beneficial.
“Today, WHO has accepted the recommendation of the International Solidarity Steering Committee to discontinue trials of hydroxychloroquine and lopinavir / ritonavir,” the WHO statement said.
Hydroxychloroquine is also used for rheumatoid diseases such as arthritis. The drug caused excitement at the beginning of the year after several small studies have shown that it can help in the treatment of coronavirus.
WHO’s decision to discontinue studies of hydroxychloroquine and lopinavir / ritonavir is only applicable to trials in hospitalized patients with coronavirus. This does not exclude the possibility of studying drugs in patients not hospitalized or as a prophylactic treatment of patients before and after exposure to coronavirus.
According to Johns Hopkins University, there is no FDA-approved medication for treating coronavirus that has infected more than 11 million people worldwide and killed at least 527,647 people.